Search Results - "Edwards, Susan T."

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-( N, N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor by Zhang, Penglie, Huang, Wenrong, Wang, Lingyan, Bao, Liang, Jia, Zhaozhong J., Bauer, Shawn M., Goldman, Erick A., Probst, Gary D., Song, Yonghong, Su, Ting, Fan, Jingmei, Wu, Yanhong, Li, Wenhao, Woolfrey, John, Sinha, Uma, Wong, Paul W., Edwards, Susan T., Arfsten, Ann E., Clizbe, Lane A., Kanter, James, Pandey, Anjali, Park, Gary, Hutchaleelaha, Athiwat, Lambing, Joseph L., Hollenbach, Stanley J., Scarborough, Robert M., Zhu, Bing-Yan

“…Systematic SAR studies of in vitro factor Xa inhibitory activity around compound 1 were performed by modifying each of the three phenyl rings. A class of…”
Get full text

Risk of early surgery for Crohn's disease: implications for early treatment strategies by Sands, Bruce E, Arsenault, Joanne E, Rosen, Michael J, Alsahli, Mazen, Bailen, Laurence, Banks, Peter, Bensen, Steven, Bousvaros, Athos, Cave, David, Cooley, Jeffrey S, Cooper, Herbert L, Edwards, Susan T, Farrell, Richard J, Griffin, Michael J, Hay, David W, John, Alex, Lidofsky, Sheldon, Olans, Lori B, Peppercorn, Mark A, Rothstein, Richard I, Roy, Michael A, Saletta, Michael J, Shah, Samir A, Warner, Andrew S, Wolf, Jacqueline L, Vecchio, James, Winter, Harland S, Zawacki, John K

“…In this study we aimed to define the rate of early surgery for Crohn's disease and to identify risk factors associated with early surgery as a basis for…”
Get full text

1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor xa inhibitors. Part 3: Design, synthesis and sar of orally bioavailable benzamidine-P4 inhibitors by JIA, Zhaozhong J, YANHONG WU, HOLLENNBACH, Stanley J, LAMBING, Joseph L, SCARBOROUGH, Robert M, ZHU, Bing-Yan, WENRONG HUANG, PENGLIE ZHANG, YONGHONG SONG, WOOLFREY, John, SINHA, Uma, ARFSTEN, Ann E, EDWARDS, Susan T, HUTCHALEELAHA, Athiwat

“…Using N,N-dialkylated benzamidines as the novel P4 motifs, we have designed and synthesized a class of 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as highly…”
Get full text

1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor xa inhibitors. Part 2: A survey of P4 motifs by JIA, Zhaozhong J, YANHONG WU, HUTCHALEELAHA, Athiwat, SCARBOROUGH, Robert M, ZHU, Bing-Yan, WENRONG HUANG, PENGLIE ZHANG, CLIZBE, Lane A, GOLDMAN, Erick A, SINHA, Uma, ARFSTEN, Ann E, EDWARDS, Susan T, ALPHONSO, Merlyn

“…A variety of P4 motifs have been examined to increase the binding affinity and in vitro anticoagulant potency of our biphenyl…”
Get full text

Inhibition of Purified Factor Xa Amidolytic Activity May Not Be Predictive of Inhibition of In Vivo Thrombosis: Implications for Identification of Therapeutically Active Inhibitors by Sinha, Uma, Lin, Pei Hua, Edwards, Susan T, Wong, Paul W, Zhu, Bingyan, Scarborough, Robert M, Su, Ting, Jia, Zhaozhong J, Song, Yonghong, Zhang, Penglie, Clizbe, Lane, Park, Gary, Reed, Andrea, Hollenbach, Stanley J, Malinowski, John, Arfsten, Ann E

“…OBJECTIVE—In this study we test the hypothesis that blood/plasma-based prothrombinase assays, rather than inhibition of purified factor Xa (fXa), are…”
Get full text

1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable benzamidine-P4 inhibitors by Jia, Zhaozhong J., Wu, Yanhong, Huang, Wenrong, Zhang, Penglie, Song, Yonghong, Woolfrey, John, Sinha, Uma, Arfsten, Ann E., Edwards, Susan T., Hutchaleelaha, Athiwat, Hollennbach, Stanley J., Lambing, Joseph L., Scarborough, Robert M., Zhu, Bing-Yan

Get full text

Differences between human and rabbit coagulation factor X—implications for in vivo models of thrombosis by Edwards, Susan T, Betz, Andreas, James, Harold L, Thompson, Erika, Yonkovich, Shirlee J, Sinha, Uma

“…The activation of factor X (fX) to factor Xa (fXa) marks the penultimate step in the coagulation cascade and modulating fXa activity may be effective for…”
Get full text

Risk of early surgery for Crohn's disease: implications for early treatment strategies by Sands, Bruce E, Arsenault, Joanne E, Rosen, Michael J, Alsahli, Mazen, Bailen, Laurence, Banks, Peter, Bensen, Steven, Bousvaros, Athos, Cave, David, Cooley, Jeffrey S, Cooper, Herbert L, Edwards, Susan T, Farrell, Richard J, Griffin, Michael J, Hay, David W, John, Alex, Lidofsky, Sheldon, Olans, Lori B, Peppercorn, Mark A, Rothstein, Richard I, Roy, Michael A, Saletta, Michael J, Shah, Samir A, Warner, Andrew S, Wolf, Jacqueline L, Vecchio, James, Winter, Harland S, Zawacki, John K

“…In this study we aimed to define the rate of early surgery for Crohn's disease and to identify risk factors associated with early surgery as a basis for…”
Get full text

Antithrombotic Activity of PRT54021, a Potent Oral Direct Factor Xa Inhibitor, Can Be Monitored Using a Novel Prothrombinase Inhibition Bioassay by Sinha, Uma, Edwards, Susan T., Wong, Paul W., Delaney, Suzanne M., Nanda, Nisha, Marzec, Ulla M., Pak, Yvonne, Hollenbach, Stanley J., Hanson, Stephen R.

“…Coagulation factor Xa (fXa) is a validated target for antithrombotic therapy and there are several on-going clinical trials testing direct fXa inhibitors…”
Get full text

Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido )-5-metho xybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor by Zhang, Penglie, Huang, Wenrong, Wang, Lingyan, Bao, Liang, Jia, Zhaozhong J, Bauer, Shawn M, Goldman, Erick A, Probst, Gary D, Song, Yonghong, Su, Ting, Fan, Jingmei, Wu, Yanhong, Li, Wenhao, Woolfrey, John, Sinha, Uma, Wong, Paul W, Edwards, Susan T, Arfsten, Ann E, Clizbe, Lane A, Kanter, James, Pandey, Anjali, Park, Gary, Hutchaleelaha, Athiwat, Lambing, Joseph L, Hollenbach, Stanley J, Scarborough, Robert M, Zhu, Bing-Yan

“…Systematic SAR studies of in vitro factor Xa inhibitory activity around compound 1 were performed by modifying each of the three phenyl rings. A class of…”
Get full text

Association between celiac sprue and cryopyrin associated autoinflammatory disorders: a case report by Shaker, Marcus, Edwards, Susan, Chionuma, Henry, Shamansky, Eric, Hoffman, Hal M

“…Cryopyrin-associated diseases may be characterized by rashes, fever, and sensorineural deafness, while celiac disease may present with symptoms of…”
Get full text

1-(2-Naphthyl)-1 H -pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs by Jia, Zhaozhong J., Wu, Yanhong, Huang, Wenrong, Zhang, Penglie, Clizbe, Lane A., Goldman, Erick A., Sinha, Uma, Arfsten, Ann E., Edwards, Susan T., Alphonso, Merlyn, Hutchaleelaha, Athiwat, Scarborough, Robert M., Zhu, Bing-Yan

Get full text